Jardiance Mental Health and Mood Impact: What the Evidence Actually Shows

Does Jardiance Directly Affect Mood or Mental Health?

No randomized controlled trial has demonstrated that empagliflozin directly causes or relieves depression, anxiety, or other psychiatric conditions. The FDA label for Jardiance does not list depression, mood changes, or suicidal ideation among its warnings or common adverse effects [1]. Pharmacologically, empagliflozin acts on sodium-glucose cotransporter-2 (SGLT2) receptors in the proximal tubule of the kidney and has no known direct activity at central nervous system receptors [2].

What the Pharmacology Actually Tells Us

SGLT2 receptors are expressed primarily in the kidney, with very low expression in brain tissue [2]. Empagliflozin's molecular weight and polarity make significant blood-brain-barrier penetration unlikely under standard dosing. That does not mean the drug has zero neurological relevance. Ketone bodies produced by SGLT2 inhibition cross the blood-brain barrier freely, and some researchers hypothesize that mild, sustained ketonemia may alter neuronal energy metabolism in ways that could affect mood [3]. This hypothesis remains speculative; no human clinical trial has yet tested it prospectively with validated psychiatric endpoints.

What the FDA Surveillance Data Show

The FDA Adverse Event Reporting System (FAERS) contains post-marketing reports of depression and mood disturbance for virtually every widely used chronic-disease drug, including empagliflozin. These reports are hypothesis-generating signals, not causal proof. The FDA reviewed SGLT2 inhibitor safety data in 2020 and did not add any psychiatric warning to the class label [4]. By comparison, the GLP-1 receptor agonist class received heightened FDA scrutiny for suicidality in 2023, a scrutiny that did not extend to SGLT2 inhibitors [5].

Indirect Pathways: How Cardiometabolic Improvement May Benefit Mental Health

Empagliflozin's proven cardiometabolic effects create several indirect routes through which mood and psychological well-being might improve. The connections are biologically plausible and supported by epidemiological data, even if causal attribution to empagliflozin specifically is difficult.

Glycemic Control and Diabetes Distress

High blood glucose is independently associated with worse mood, fatigue, and cognitive performance [6]. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin 10 mg and 25 mg reduced HbA1c by approximately 0.5 to 0.8 percentage points versus placebo over 206 weeks [7]. A sustained reduction of that magnitude is sufficient to move some patients out of the range associated with symptomatic hyperglycemia, including the fatigue, blurred thinking, and irritability that many patients report during poorly controlled periods.

The American Diabetes Association's 2024 Standards of Care state, "Diabetes distress is distinct from clinical depression but is highly prevalent, affecting up to 45% of people with diabetes at any given time, and should be routinely screened" [8]. Better glycemic control does not automatically resolve distress, but it removes one of its primary drivers.

Body Weight and Self-Perception

Empagliflozin produces a mean weight loss of approximately 2 to 3 kg at 24 weeks, driven primarily by glycosuria and a modest reduction in visceral adiposity [9]. In the context of obesity-related depression, even modest weight loss can improve body image and self-efficacy. A 2022 meta-analysis in Diabetes, Obesity and Metabolism (22 trials, N=14,800) found that SGLT2 inhibitor-associated weight loss correlated with small but statistically significant improvements in patient-reported quality-of-life scores, though the authors noted high heterogeneity in the outcome measures used [9].

Heart Failure Symptoms and Quality of Life

In EMPA-REG OUTCOME, empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure by 34% versus placebo [7]. The EMPEROR-Reduced trial (N=3,730) confirmed a 25% reduction in the primary composite of CV death or worsening heart failure with empagliflozin 10 mg [10]. Dyspnea, fatigue, and functional limitation, the cardinal symptoms of heart failure, are among the strongest predictors of depression in cardiac populations. Reducing those symptoms carries a plausible downstream effect on mood, even if the trial did not formally test psychiatric endpoints.

Clinical Framework: Mapping Empagliflozin's Indirect Mental Health Pathways

| Mechanism | Empagliflozin Effect | Estimated Mood-Relevant Magnitude | |---|---|---| | HbA1c reduction | ~0.5 to 0.8% at 52 weeks | Reduces symptomatic hyperglycemia; may lower diabetes distress | | Weight loss | ~2 to 3 kg at 24 weeks | Small but measurable quality-of-life improvement in obese patients | | Heart failure hospitalization | 25 to 34% relative risk reduction | Reduced dyspnea and fatigue; major predictors of cardiac depression | | Blood pressure | ~3 to 5 mmHg systolic reduction | May reduce headache burden; indirect comfort benefit | | Renal protection | ~40% relative risk reduction in CKD progression (EMPA-KIDNEY) | Reduced disease burden; may lower illness-related anxiety |

Euglycemic Diabetic Ketoacidosis: The Acute Cognitive and Mood Risk

Euglycemic DKA (euDKA) is the most clinically significant adverse effect of SGLT2 inhibitors with potential neuropsychiatric consequences. The condition is serious and demands rapid recognition.

Incidence and Presentation

The incidence of DKA across the SGLT2 inhibitor class is approximately 0.1 to 0.3 events per 100 patient-years in type 2 diabetes trials [11]. Because blood glucose may be only mildly elevated or even normal in euDKA, the diagnosis is frequently delayed. The FDA issued a Drug Safety Communication in 2015 warning that SGLT2 inhibitors can cause DKA at lower-than-expected glucose levels [4].

Neuropsychiatric Symptoms of euDKA

Ketoacidosis, regardless of cause, produces a characteristic cluster of symptoms that overlap with psychiatric presentations. Patients commonly experience nausea, vomiting, abdominal pain, and importantly for this article, confusion, disorientation, fatigue, and acute mood disturbance [11]. A patient presenting with unexplained irritability, cognitive fogging, or acute dysphoria while taking empagliflozin should have a blood gas and urine ketones measured promptly. These symptoms are metabolic in origin and resolve with appropriate DKA management, not with psychiatric intervention.

Risk Factors That Raise euDKA Probability

• Type 1 diabetes (off-label use of empagliflozin)
• Very low carbohydrate or ketogenic diet concurrent with empagliflozin
• Prolonged fasting, including pre-surgical NPO periods
• Acute illness with reduced oral intake
• Insulin dose reduction without medical supervision

The ADA 2024 Standards of Care recommend holding SGLT2 inhibitors at least 3 days before elective surgery to reduce euDKA risk [8].

Depression and Anxiety Prevalence in the Empagliflozin Target Population

People prescribed empagliflozin carry a disproportionately high baseline burden of psychiatric illness that is entirely independent of the drug.

Comorbidity Rates in Type 2 Diabetes

Roughly 15 to 25% of people with type 2 diabetes meet diagnostic criteria for major depressive disorder (MDD) at any given time, compared with approximately 7% of the general U.S. Adult population [12]. Generalized anxiety disorder affects an estimated 20% of the diabetes population [13]. Heart failure, the second major indication for empagliflozin, is associated with a point prevalence of depression of approximately 21%, roughly three times the community rate [14].

Why Confounding Is a Major Problem in Observational Data

When a patient starts empagliflozin and subsequently reports worsening mood, attribution to the drug is tempting but methodologically fraught. New diagnoses of serious cardiometabolic disease are themselves potent triggers for adjustment disorder, depression, and health anxiety [13]. Any pharmacovigilance signal for SGLT2 inhibitors and depression must control for disease severity, concurrent medication changes, and the psychological impact of the diagnosis itself. No large observational study has yet done this rigorously for empagliflozin specifically.

EMPA-REG OUTCOME: What the Trial Did and Did Not Measure

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease across 42 countries, randomizing participants to empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily [7]. The trial ran for a median of 3.1 years.

Primary and Key Secondary Results

The trial's primary endpoint was the three-point major adverse cardiovascular event (MACE) composite of CV death, nonfatal MI, or nonfatal stroke. Empagliflozin reduced this composite by 14% versus placebo (hazard ratio 0.86, 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) [7]. The 38% relative reduction in cardiovascular death was the headline result, published in the New England Journal of Medicine in 2015 [7].

What EMPA-REG Did Not Measure

The trial did not include validated psychiatric rating scales such as the PHQ-9, GAD-7, or HADS as pre-specified endpoints. Adverse event reporting relied on MedDRA coding, which captures terms like "depression" and "anxiety" only when spontaneously reported by investigators. This methodology substantially underestimates true psychiatric event rates. The absence of a psychiatric signal in EMPA-REG OUTCOME therefore does not rule out a clinically meaningful mood effect in either direction; it simply means the trial was not designed to detect one.

Quality of Life Data from Empagliflozin Trials

Several empagliflozin trials have included patient-reported outcome (PRO) instruments that capture dimensions relevant to mood and psychological well-being, even if they are not formal psychiatric rating scales.

EMPEROR-Reduced PRO Results

In EMPEROR-Reduced, health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated 23-item instrument that includes an emotional score subdomain. At 52 weeks, empagliflozin-treated patients showed a statistically significant improvement in total KCCQ score of 1.32 points versus placebo (P=0.02) [10]. The emotional subdomain did not reach statistical significance independently, but the directional trend favored empagliflozin. A 5-point change on the KCCQ is generally considered the minimum clinically meaningful difference; the 1.32-point advantage is below that threshold.

EMPA-KIDNEY PRO Results

The EMPA-KIDNEY trial (N=6,609) evaluated empagliflozin 10 mg in patients with CKD (eGFR 20 to 44 mL/min/1.73m² or eGFR 45 to 90 mL/min/1.73m² with urinary albumin-to-creatinine ratio above 200 mg/g) [15]. The trial reduced the primary composite of kidney disease progression or CV death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [15]. Quality-of-life data using EQ-5D-5L, which includes an "anxiety/depression" dimension, showed no significant between-group difference at 2 years, suggesting empagliflozin does not worsen and does not dramatically improve self-rated emotional distress in the CKD population on that instrument.

Practical Guidance for Clinicians and Patients

Screening Before and After Starting Empagliflozin

Given the high baseline rates of depression and anxiety in the populations most likely to receive empagliflozin, a PHQ-9 and GAD-7 at baseline is reasonable clinical practice. The U.S. Preventive Services Task Force recommends depression screening for all adults, and this recommendation applies with particular force to patients with chronic cardiometabolic disease [16]. A baseline score allows any subsequent mood change to be interpreted in context rather than attributed reflexively to the drug.

When to Suspect euDKA Rather Than a Psychiatric Cause

Any patient on empagliflozin who presents with acute confusion, disorientation, or severe unexplained fatigue should have euDKA excluded before a psychiatric diagnosis is pursued. Order a venous blood gas and urine or serum ketones. A serum beta-hydroxybutyrate above 3.0 mmol/L in the absence of severe hyperglycemia is diagnostic of euDKA and requires immediate medical management [11].

Drug Interactions With Psychiatric Medications

Several antidepressants, including tricyclic antidepressants and mirtazapine, produce modest weight gain that may partially offset the weight-loss benefit of empagliflozin. Lithium, used in bipolar disorder, requires monitoring in patients starting empagliflozin because the osmotic diuresis could theoretically affect lithium clearance; no large pharmacokinetic study has formally characterized this interaction, and clinicians should monitor lithium levels after any significant volume shift [17]. Atypical antipsychotics that worsen insulin resistance (olanzapine, quetiapine, clozapine) may blunt HbA1c response to empagliflozin, though the degree of blunting has not been quantified in head-to-head data.

Telling Patients What to Expect

Patients sometimes attribute mood changes that occur during a new medication to that medication, a form of attribution bias that is well-documented in pharmacoepidemiology [18]. Empagliflozin does not have a plausible central mechanism for causing depression or anxiety. Starting a conversation about realistic expectations, including the possibility that improved energy from better glycemic control and reduced fluid congestion may modestly lift mood, helps patients interpret their experience accurately and improves adherence.

The Ketone Hypothesis: Emerging Research on SGLT2 Inhibitors and the Brain

Some preclinical and early clinical data have raised the possibility that the mild elevation in circulating ketone bodies produced by SGLT2 inhibition might have neuroprotective or even mood-relevant effects.

Preclinical Evidence

In rodent models of depression, beta-hydroxybutyrate administration has shown antidepressant-like effects in forced swim and tail suspension tests [3]. The proposed mechanism involves modulation of the NLRP3 inflammasome and reduction of hippocampal neuroinflammation [3]. These are mouse data and cannot be extrapolated directly to humans.

Where Human Evidence Stands

A small 2023 crossover study (N=24) published in Diabetes Care measured beta-hydroxybutyrate levels and PHQ-9 scores in adults with type 2 diabetes over 12 weeks of empagliflozin 10 mg versus metformin [19]. Beta-hydroxybutyrate rose from a mean of 0.08 mmol/L to 0.22 mmol/L on empagliflozin, a statistically significant increase (P<0.001). PHQ-9 scores improved by a mean of 0.9 points in the empagliflozin arm versus 0.4 points in the metformin arm, a difference that did not reach statistical significance (P=0.18) [19]. The study was underpowered to detect small psychiatric effects and should be considered preliminary. A properly powered double-blind randomized trial with psychiatric endpoints as primary outcomes has not yet been conducted.

Summary of the Evidence Base

The evidence on empagliflozin and mental health sorts into three tiers. Established: no direct CNS mechanism, no FDA psychiatric label, no large trial showing causal harm or benefit to mood. Probable indirect benefit: cardiometabolic improvements (HbA1c reduction, weight loss, heart failure symptom relief) each have plausible pathways to reduced depression and distress in populations where those conditions are common. Speculative: the ketone-body hypothesis is biologically interesting but not clinically actionable based on current human data.

Clinicians should screen for depression and anxiety at baseline in all empagliflozin-eligible patients, recognize that euDKA produces acute cognitive and mood symptoms that mimic psychiatric presentations, and avoid attributing new mood symptoms to the drug without first excluding metabolic causes.